Blaze.tech just secured $8.5M in pre-seed funding to build AI-powered, HIPAA-compliant app development tooling. It won’t be the last round like it. The pitch writes itself: healthcare software is expensive and slow, AI plus no-code makes it cheap and fast, compliance comes baked in. Founders in our world — funded virtual-care companies trying to ship — are going to hear that pitch a lot over the next two years.
Here’s the thing: we’re not going to tell you the pitch is wrong. Parts of it are genuinely right, and pretending otherwise would be an agency protecting its lunch. So let’s be precise about what these tools do well, where they hit the wall, and why the wall is where it is.
What they’re genuinely good at: testing the water
Low-code and no-code platforms are typically very focused on solving a specific problem, and they can solve it well. If the question is “does this idea have legs?”, they’re a great answer. You get something in front of real users quickly, without much investment, and you learn whether the idea deserves a place in your product at all. That’s not a consolation prize — killing a bad idea for $10K instead of $200K is one of the highest-ROI things an early company can do.
We’d honestly recommend them for that. Validate the theory. Build the internal ops tool. Stand up the quick patient check-in form.
Where the wall is: evolution, not launch
The problems come later, and they’re predictable, because we’ve inherited them. The typical failure isn’t that the no-code tool couldn’t build v1 — it’s that the tool couldn’t become v2. Business requirements evolve. The solution needs to grow, and the platform has it stuck on rails. Pivoting means fighting the tool. Eventually it means re-architecture, data migration, testing, verification, and monitoring — the full cost you deferred, plus interest, plus the operational risk of migrating a live healthcare product.
Here’s a concrete shape of the wall. A quick tool for patients to self-report how they’re doing? A no-code platform handles that fine. Now expand it into a clinical feedback loop: longitudinal views across self-reported check-ins, lab results arriving from multiple partners in different formats, wearable data streams — some sources that exist today, some that haven’t been thought of yet. Systems have to evolve to absorb that, and evolution is exactly where template-shaped tools break down.
And that’s before the parts of healthcare that resist abstraction entirely: pharmacy integrations that behave differently by partner, insurance rails, state-by-state regulatory variation, EPCS, clinical-ops workflows that are weird because medicine is weird. A platform can stamp “HIPAA-compliant” on its hosting. It cannot stamp it on your incident response plan, your data retention policy, your vendor BAA chain, or the workflow decisions your product makes — most of compliance lives outside the codebase, and no tool ships it for you.
The metaphor we keep coming back to: these tools are great for testing the water. But if the water’s nice and you jump in, and then the storm rolls in — what do you do?
The real distinction: who’s driving
Here’s where we have to be honest about our own house. Fanzoo’s delivery is AI-accelerated. We use this technology aggressively, and it makes us dramatically faster. So the difference between us and the no-code pitch can’t be “AI tooling bad.”
It isn’t. The difference between low/no-code and AI-accelerated development is who’s driving. The technology is great. It is simply more effective in the hands of trained system builders than in the hands of someone who hasn’t worn that hat. Experience is what lets you see the road ahead before you get there — and plan for it.
That planning sounds like questions the tool will never ask you:
- You’re testing the water — what’s your plan if the test succeeds? What can you do now, cheaply, to make the transition easier?
- If it fails, what’s your fallback, and what data do you need to carry out of the wreckage?
- How do you architect today’s version so it doesn’t cost 5x more to evolve later?
None of those are code questions. They’re judgment questions. The tool generates the app; it doesn’t generate the foresight. A seed-stage healthcare product built by an experienced team using AI acceleration and a product built by a template using the same AI can look identical in a demo. They diverge the first time requirements change — which, in healthcare, is roughly week three.
The practical takeaway
If you’re a founder: use the no-code tool to validate. Genuinely. But go in knowing what it’s for — it’s a hypothesis test, not a foundation — and decide before you build what success triggers. The most expensive sentence in early-stage healthcare software is “we’ll just keep building on what we have,” said about a prototype that was never designed to be built on.
And when the test comes back positive, the question stops being “can we ship an app?” — anyone can now — and becomes “who’s driving?”
Fanzoo is a senior engineering team that builds virtual-care products end to end — AI-accelerated, HIPAA-aware, and architected to evolve. If you’ve validated an idea and need to build the real thing, the Launch Path is our fixed-price way to plan it before you pay to build it.